Egetis Gets Conditional FDA Name Acceptance

ReutersApr 8, 2026 11:21 AM

April 8 (Reuters) - Egetis Therapeutics AB (publ) EGTX.ST:

RECEIVES CONDITIONAL FDA ACCEPTANCE OF PROPRIETARY NAME EMCITATE
FINAL APPROVAL OF EMCITATE NAME RESERVED UNTIL NDA APPROVAL
APPLICATION GRANTED PRIORITY REVIEW WITH PDUFA DATE OF SEPTEMBER 28, 2026

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Tradingkey

Recommended Articles

US-Iran Truce, Gold Prices Return to $4,800, Is Now Still the Time to Buy?

TradingKey - On the evening of April 7, Eastern Time, Trump announced his agreement to a two-week ceasefire, leading to a recovery in precious metals. Spot gold (XAUUSD) broke above $4,800, while spot silver rose nearly 5%. Simultaneously, international oil prices plummeted, with Brent crude futures seeing a maximum decline of nearly 18% and WTI crude futures falling over 19%.

Ceasefire Expectations Push Oil Prices Below $100, Intraday Drop Near $20, Where Do Oil Prices Go Next?

TradingKey - The core driver of this round of oil price declines is not a sudden weakening of supply and demand data, but rather a swift correction of the market's worst-case expectations for the Middle East situation.

Apple Shares Plunge 5% After Foldable iPhone Engineering Scare—Where is the Next 'iPhone Moment'?

TradingKey - During the April 7 US trading session, Apple (AAPL) shares fell more than 5% intraday, hitting a low of $245.7. A report from Nikkei indicated that Apple encountered setbacks during the engineering testing phase of its first foldable iPhone, which could potentially delay mass production

Anthropic Revenue Surpasses OpenAI for First Time, IPO as Early as October

TradingKey - April 7, 2026, Anthropic released two major updates: **Stellar Performance:** Annualized revenue surpassed $30 billion, exceeding OpenAI’s $25 billion, making it the world's highest-earning AI unicorn. **Computing Power Secured:** Reached new agreements with Broadcom and Google to sec

Meta Is About to Launch a Consumer-Facing AI Model, and OpenAI Is About to Have Its IPO, Making Now a Good Time to Buy Meta Stock

TradingKey - As of April 07, 2026, the stock price of Meta Platforms, Inc. (NASDAQ:META) is approximately $573. The second half of 2025 was a great period for this stock as it increased nearly 12%. However, in Q1 of 2026, Meta's stock dropped 13.5%, which was the largest decline since Q4 of 2022.

Tradingkey

KeyAI

